サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427993

レミケードバイオシミラーの世界市場レポート2024

Remicade Biosimilar Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
レミケードバイオシミラーの世界市場レポート2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

レミケードバイオシミラーの市場規模は、今後数年間で急激に成長すると予想されています。 2028年には22.9%の年間複合成長率（CAGR）で91億米ドルに成長すると予想されます。予測期間で予想される成長は、特許の有効期限、費用対効果の高い治療法に対する需要の増加、バイオシミラーパイプラインの進行中の開発、償還政策、市場の統合などの要因に起因すると考えられます。予測期間中に予想される重要な動向には、医師の処方行動の影響、バイオシミラーのライフサイクル管理、バイオシミラーの命名規則に関連する考慮事項、バイオシミラーの互換性の決定、バイオシミラーの情勢における現実世界の証拠の重要性などが含まれます。

自己免疫疾患の発生率の増加により、レミケードバイオシミラー市場の成長が促進される見込みです。自己免疫疾患には、免疫系が誤って攻撃し、体の組織や器官に損傷を与えることが関係します。 レミケードバイオシミラーは、自己免疫疾患に関連する症状を管理し、炎症を軽減するための効果的な治療オプションを提供します。特に、2021年10月のロンドン市立大学の報告書によると、英国では7％に相当する400万人が自己免疫疾患に罹患しており、80を超える自己免疫疾患が確認されており、有病率は年間3～9％増加していることが示されています。同様に、クリーブランドクリニックは、2021年7月に米国で15人に1人が自己免疫疾患に罹患しており、クローン病、潰瘍性大腸炎、狼瘡などの特定の疾患は数百万人に影響を及ぼしていると報告しました。この自己免疫疾患の増加は、レミケードバイオシミラー市場の重要な推進力です。

ヘルスケア支出の大幅な増加は、レミケードバイオシミラー市場の成長に貢献する重要な要因です。ヘルスケア支出とは、特定の期間（通常は毎年）におけるヘルスケア製品およびサービスに対する合計支出を指します。レミケードを含む生物製剤は高価になる可能性があるため、コストの抑制と資源効率への注目が高まっています。レミケードなどのバイオシミラーは、先発品のバイオ医薬品に代わる、よりコスト効率の高い代替品を提供します。たとえば、2023年6月のメディケア・メディケイドサービスセンター（CMS）のデータによると、米国の国民医療支出（NHE）は2021年に4兆3,000億米ドルに達し、GDPの18.3％を占めました。このヘルスケア支出の増加により、レミケードバイオシミラー市場が牽引されると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のレミケードバイオシミラー市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 100mg/10ml
  • 500mg/50ml
  • 世界のレミケードバイオシミラー市場、疾患適応別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 潰瘍性大腸炎
  • 関節リウマチ
  • 強直性脊椎炎
  • クローン病
  • 乾癬性関節炎
  • 尋常性乾癬
  • 世界のレミケードバイオシミラー市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 血液疾患
  • 腫瘍学疾患

第7章 地域および国の分析

  • 世界のレミケードバイオシミラー市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のレミケードバイオシミラー市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • レミケードバイオシミラー市場の競合情勢
  • レミケードバイオシミラー市場の企業プロファイル
    • AbbVie Inc.
    • Novartis AG
    • Amgen Inc
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.

第31章 その他の大手および革新的な企業

  • Biogen Inc.
  • Organon &Co.
  • Merck And Co. Inc.
  • Janssen Biotech Inc.
  • LG Chem Ltd.
  • Nippon Kayaku Co. Ltd.
  • Celltrion Inc.
  • Nichi-iko Pharmaceutical Co. Ltd.
  • Biocon Limited
  • Alvogen Inc
  • Synthon International Holding BV
  • Coherus Biosciences Inc
  • Cardinal Health Inc
  • Genentech Inc.
  • Alvotech SA

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13837

A Remicade biosimilar is a biological drug that is similar to Remicade, and it is utilized in the treatment of certain autoimmune diseases in both adults and children. This type of medication is specifically designed to address autoimmune inflammatory conditions such as psoriasis, rheumatoid arthritis, Crohn's disease, and ulcerative colitis.

The main types of biosimilars in the Remicade biosimilars category come in strengths of 100 mg/10 ml and 500 mg/50 ml. The 100 mg/10 ml strength indicates the amount of drug in the dosage form or a unit of the dosage form, equivalent to 100 mg per 10 ml. The applications for these biosimilars include the treatment of conditions such as ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis, and plaque psoriasis. Additionally, they are used for various applications in the treatment of blood disorders and oncology diseases.

The remicade biosimilars market research report is one of a series of new reports from The Business Research Company that provides remicade biosimilars market statistics, including remicade biosimilars industry global market size, regional shares, competitors with a remicade biosimilars market share, detailed remicade biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the remicade biosimilars industry. This remicade biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The remicade biosimilar market size has grown exponentially in recent years. It will grow from $3.2 billion in 2023 to $3.99 billion in 2024 at a compound annual growth rate (CAGR) of 24.4%. The increase observed in the historical period can be attributed to factors such as the introduction of Remicade (infliximab), advancements in biotechnology, the expiry of patents for biologics, the establishment of regulatory pathways, and pressures related to healthcare costs.

The remicade biosimilar market size is expected to see exponential growth in the next few years. It will grow to $9.1 billion in 2028 at a compound annual growth rate (CAGR) of 22.9%. The anticipated growth in the forecast period can be attributed to factors such as patent expirations, an increasing demand for cost-effective therapies, ongoing development in the biosimilar pipeline, reimbursement policies, and market consolidation. Significant trends expected during the forecast period include the influence of physician prescribing behavior, biosimilar lifecycle management, considerations related to biosimilar naming conventions, the determination of biosimilar interchangeability, and the importance of real-world evidence in the biosimilar landscape.

The increasing incidence of autoimmune diseases is poised to drive the growth of the Remicade biosimilar market. Autoimmune diseases involve the immune system mistakenly attacking and causing damage to the body's tissues and organs. Remicade biosimilars offer an effective therapeutic option for managing symptoms and reducing inflammation associated with autoimmune diseases. Notably, reports from the City University of London in October 2021 indicated that in the UK, 4 million people, or 7%, suffered from autoimmune diseases, with over 80 identified autoimmune illnesses exhibiting an annual prevalence increase of 3-9%. Similarly, the Cleveland Clinic reported that autoimmune diseases affected 1 in 15 people in the US in July 2021, with specific conditions such as Crohn's disease, ulcerative colitis, and lupus impacting millions. This rise in autoimmune diseases is a significant driver for the Remicade biosimilar market.

The substantial increase in healthcare expenditure is a key factor contributing to the growth of the Remicade biosimilar market. Healthcare expenditure refers to the total spending on healthcare goods and services over a specific period, usually annually. Biologic drugs, including Remicade, can be costly, prompting a greater focus on cost containment and resource efficiency. Biosimilars, such as those for Remicade, offer a more cost-effective alternative to originator biologics. For instance, data from the Centers for Medicare & Medicaid Services (CMS) in June 2023 revealed that the national health expenditure (NHE) in the United States reached $4.3 trillion in 2021, accounting for 18.3% of GDP. This growing healthcare expenditure is expected to drive the Remicade biosimilar market.

Innovation in product development is a notable trend in the Remicade biosimilar market, with major companies focusing on introducing innovative products to maintain their market position. An example is Amgen Inc., a US-based biotechnology company, which launched Amjevita in January 2023. Amjevita is a biosimilar version of AbbVie's Humira, designed to be as safe and effective as the original drug. With a lower cost than Humira, Amjevita offers patients a more affordable treatment option for autoimmune diseases such as rheumatoid arthritis and Crohn's disease.

A trend in the Remicade biosimilar market is the focus on developing biosimilars for Humira drugs, a class of medications used to treat various conditions, including arthritis. Major companies are leveraging regulatory approvals to broaden their market presence. For example, in February 2021, the U.S. FDA approved an efficacy supplement for HUMIRA (adalimumab) injection, extending its indication for pediatric patients with moderately to severely active ulcerative colitis. Additionally, in April 2023, the European Commission granted marketing authorization for a citrate-free high concentration formulation of Hyrimoz, a biosimilar of adalimumab. These regulatory approvals contribute to the growth of the Humira drug market.

In April 2022, Samsung Biologics, a South Korea-based biotechnology company, acquired Samsung Bioepis Co. Ltd. for $2.3 billion. This acquisition positions Samsung Biologics to meet the increasing demand for biosimilars, access a broader range of products, expand manufacturing capacity, and strengthen its global reach. Samsung Bioepis Co. Ltd. is a South Korea-based biopharmaceutical company specializing in producing Remicade biosimilar products.

Major companies operating in the remicade biosimilar market report are AbbVie Inc., Novartis AG, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Organon & Co., Merck And Co. Inc., Janssen Biotech Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvogen Inc., Synthon International Holding B.V., Coherus Biosciences Inc., Cardinal Health Inc., Genentech Inc., Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd., Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

Europe was the largest region in the remicade biosimilar market in 2023. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the remicade biosimilar market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The remicade biosimilar market consists of sales of inflectra, renflexis, avolsa, remsima, infimab, and avolsa. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Remicade Biosimilar Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on remicade biosimilar market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for remicade biosimilar ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The remicade biosimilar market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: 100mg/10ml; 500mg/50ml
  • 2) By Disease Indication: Ulcerative Colitis; Rheumatoid Arthritis; Ankylosing Spondylitis; Crohn's Disease; Psoriatic Arthritis; Plaque Psoriasis
  • 3) By Application: Blood Disorders; Oncology Diseases
  • Companies Mentioned: AbbVie Inc.; Novartis AG; Amgen Inc; Viatris Inc.; Teva Pharmaceutical Industries Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Remicade Biosimilar Market Characteristics

3. Remicade Biosimilar Market Trends And Strategies

4. Remicade Biosimilar Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Remicade Biosimilar Market Size and Growth

  • 5.1. Global Remicade Biosimilar Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Remicade Biosimilar Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Remicade Biosimilar Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Remicade Biosimilar Market Segmentation

  • 6.1. Global Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 100mg/10ml
  • 500mg/50ml
  • 6.2. Global Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Ulcerative Colitis
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis
  • Crohn's Disease
  • Psoriatic Arthritis
  • Plaque Psoriasis
  • 6.3. Global Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Blood Disorders
  • Oncology Diseases

7. Remicade Biosimilar Market Regional And Country Analysis

  • 7.1. Global Remicade Biosimilar Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Remicade Biosimilar Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Remicade Biosimilar Market

  • 8.1. Asia-Pacific Remicade Biosimilar Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Remicade Biosimilar Market

  • 9.1. China Remicade Biosimilar Market Overview
  • 9.2. China Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Remicade Biosimilar Market

  • 10.1. India Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Remicade Biosimilar Market

  • 11.1. Japan Remicade Biosimilar Market Overview
  • 11.2. Japan Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Remicade Biosimilar Market

  • 12.1. Australia Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Remicade Biosimilar Market

  • 13.1. Indonesia Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Remicade Biosimilar Market

  • 14.1. South Korea Remicade Biosimilar Market Overview
  • 14.2. South Korea Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Remicade Biosimilar Market

  • 15.1. Western Europe Remicade Biosimilar Market Overview
  • 15.2. Western Europe Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Remicade Biosimilar Market

  • 16.1. UK Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Remicade Biosimilar Market

  • 17.1. Germany Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Remicade Biosimilar Market

  • 18.1. France Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Remicade Biosimilar Market

  • 19.1. Italy Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Remicade Biosimilar Market

  • 20.1. Spain Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Remicade Biosimilar Market

  • 21.1. Eastern Europe Remicade Biosimilar Market Overview
  • 21.2. Eastern Europe Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Remicade Biosimilar Market

  • 22.1. Russia Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Remicade Biosimilar Market

  • 23.1. North America Remicade Biosimilar Market Overview
  • 23.2. North America Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Remicade Biosimilar Market

  • 24.1. USA Remicade Biosimilar Market Overview
  • 24.2. USA Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Remicade Biosimilar Market

  • 25.1. Canada Remicade Biosimilar Market Overview
  • 25.2. Canada Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Remicade Biosimilar Market

  • 26.1. South America Remicade Biosimilar Market Overview
  • 26.2. South America Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Remicade Biosimilar Market

  • 27.1. Brazil Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Remicade Biosimilar Market

  • 28.1. Middle East Remicade Biosimilar Market Overview
  • 28.2. Middle East Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Remicade Biosimilar Market

  • 29.1. Africa Remicade Biosimilar Market Overview
  • 29.2. Africa Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Remicade Biosimilar Market Competitive Landscape And Company Profiles

  • 30.1. Remicade Biosimilar Market Competitive Landscape
  • 30.2. Remicade Biosimilar Market Company Profiles
    • 30.2.1. AbbVie Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Novartis AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Amgen Inc
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Viatris Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Teva Pharmaceutical Industries Ltd.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Remicade Biosimilar Market Other Major And Innovative Companies

  • 31.1. Biogen Inc.
  • 31.2. Organon & Co.
  • 31.3. Merck And Co. Inc.
  • 31.4. Janssen Biotech Inc.
  • 31.5. LG Chem Ltd.
  • 31.6. Nippon Kayaku Co. Ltd.
  • 31.7. Celltrion Inc.
  • 31.8. Nichi-iko Pharmaceutical Co. Ltd.
  • 31.9. Biocon Limited
  • 31.10. Alvogen Inc
  • 31.11. Synthon International Holding B.V.
  • 31.12. Coherus Biosciences Inc
  • 31.13. Cardinal Health Inc
  • 31.14. Genentech Inc.
  • 31.15. Alvotech S.A.

32. Global Remicade Biosimilar Market Competitive Benchmarking

33. Global Remicade Biosimilar Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Remicade Biosimilar Market

35. Remicade Biosimilar Market Future Outlook and Potential Analysis

  • 35.1 Remicade Biosimilar Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Remicade Biosimilar Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Remicade Biosimilar Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer